medigraphic.com

2014, Number 3

<< Back Next >>

Rev Cuba Endoc 2014; 25 (3)

Replacement treatment for chronic adrenal failure

Nuez VM

Language: Spanish
References: 23
Page: 191-197
PDF size: 84.92 Kb.


ABSTRACT

Chronic adrenal failure is a disease characterized by shortage of adrenal cortex hormones. It requires lifelong replacement treatment to overcome this shortage in order to enjoy quality normal life. For the replacement treatment to be successful, it is very important to learn about its guidelines and variants, which is a useful tool in the daily work of physicians. Knowing the present trends is indispensable; therefore, the objective of this paper was to review the different treatment variants that may be used in this group of patients.


REFERENCES

  1. Bovillon R. Acute adrenal insufficiency. Endocrinol Metab Clin North Am 2006;35:767-75.

  2. Hahner S, Loeffler M, Fassnacht W, Koschker AC, Quinkler M, Decker O, et al. Impairet subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J Clin Endocrinol Metab. 2007;92:3912-22.

  3. Bergthorsdottir R, Leonson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison’s disease: a population based study. J Clin Endocrinol Metab. 2006;91:4839-53.

  4. Majeroni BA, Patel P. Autoinmune polyglandular syndrome, type II. Am Farm Physician. 2007;75:667-70.

  5. Arit W. The approach to the adult with newly diagnosed adrenal insufficiency. J Clin Endocrinol Metab. 2009;94:1059-67.

  6. Rodríguez K. Insuficiencia suprarrenal. En: Rodríguez Silva H y Pérez Caballero D. Manual de Diagnóstico y Tratamiento en Especialidades Clínicas. La Habana: Editora Política; 2002. p. 167-8.

  7. Salvatori R. Adrenal insufficiency. Jaam. 2005;194:2481-8.

  8. Stewart PM. The adrenal cortex. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, eds. Textbook of Endocrinology. 11na edition. Philadephia: Williams; 2008. p. 445-504.

  9. Besser GM, Jeffcoate WJ. Endocrine and metabolic diseases Adrenal diseases. BMJ. 1976;1:448-51.

  10. Kenny KM, Taylor FH, Richards C. Reference standards for cortisol production and 17-hydroxy-corticosteroid excretion during growth: variation in the pattern of excretion of radiolabeled cortisol metabolites of radiolabeled cortisol metabolites. Hormo Research. 2007 (Suppl 4):280-90.

  11. Cope CL, Pearson J. Clinical value of cortisol secretion. J Clin Pathol. 1965;18:82-7.

  12. Zummoff B, Fukushima DK, Hellman L. Intercomparison of four methods for measuring cortisol production. J Clin Endocrinol Metab. 1974;38:169-75.

  13. Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Boothe JD, Winterer JC, et al. Daily cortisol production rate in man determined by stable isotope dillution/mass spectrometry. J Clin Endocrinol Metab. 1991;72:39-45.

  14. Lovas K, Gjesdal CG, Christensen M. Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur J Endocrinol. 2009;160:993-1002.

  15. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrin Metab. 2008;93:400-9.

  16. Oster H, Damerow S, Kiessling S, Memmott A, Doane A, Ibbotson V, et al. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia. Clinical Endocrinology. 2006;65:45-50.

  17. Weitzman ED, Fukushima D, Nogeire C, Roffwarg H, Gallagher TH, Hellman J. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab. 1971;33:14-22.

  18. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A, Ibbotson V, et al. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clinical Endocrinology. 2004;6:1337-67.

  19. Feek CM, Ratcliffe JG, Seth J, Gray CE, Toft AD, Irvine WJ. Patterns of plas cortisol and ACTH concentrations in patients with Addison’s disease treated with conventional corticosteroid replacement. Clinical Endocrinology. 1981;14:451-8.

  20. Nickelsen T, Schulz F, Demisch K. Studies on cortisol substitution therapy in patients with adrenal insufficiency. Experimental and Clinical Endocrinology. 1983;82:35-41.

  21. Johannsson G, Filipsson H, Bergthorsdottir R, Lennernas H, Skrtic S. Longacting hydrocortisone for glucocorticoid replacement therapy. Hormo Research. 2007;68 (Supplement 5):2-188.

  22. Dubois EF, Derks MG, Schweitzer DH, Zwinderman AH, Dekhuijzen PN, Van Boxtel CJ. Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men. European Journal of Clinical Pharmacology. 2004;60:315-28.

  23. Newell-Price J, Whiteman M, Rostami-Hodjegan A, Darzy K, Shalet S, Tucker G, et al. Modified-release hydrocortisone for circadian therapy: a proof-of-principle study in dexamethasone suppressed normal volunteers. Clinical Endocrinology. 2008;68:130-135.




2020     |     www.medigraphic.com